Jimmy Everest Center for Cancer and Blood Disorders, Oklahoma City, Oklahoma.
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Pediatr Blood Cancer. 2018 Aug;65(8):e27095. doi: 10.1002/pbc.27095. Epub 2018 Apr 25.
Second neoplasms (SNs) are a well-established long-term adverse effect of radiation therapy (RT), but there are limited data regarding their incidence and location relative to the radiation field, specific to medulloblastoma (MB) survivors after craniospinal irradiation (CSI).
A systematic literature review, per Preferred Reporting Items for Systematic Reviews and Meta-Analyses, identified six studies reporting the incidence and locations of SNs for 1,114 patients with MB, after CSI, with a median follow-up of ∼9 years (7.6-15.4 years). The study-specific cumulative incidence (CI) of SNs, second benign neoplasms (SBNs), and second malignant neoplasms (SMNs) were standardized to a 10-year time frame. Meta-analysis was performed using random effects models, with pooled data from selected studies and an institutional cohort of 55 patients.
The 10-year CI was 6.1% for all SNs (excluding skin cancer and leukemia), 3.1% for SBNs, and 3.7% for SMNs. Fifty-eight percent of SNs were malignant; high-grade glioma was the most common SMN (15/33; 45%) and meningioma, the most common SBN (16/24; 67%). Forty percent of SNs occurred outside the target central nervous system (CNS) field, with a majority in areas of exit RT dose. Seventy-four percent of extra-CNS tumors (17/23) were malignant, most commonly thyroid carcinoma (7/17; 41%) and bone and soft-tissue tumors (6/17, 35%).
Survivors of MB are at risk of SNs both within and outside the CNS. A significant proportion of SNs occur in areas of exit RT dose. Studies are needed to determine whether the use of proton therapy, which has no exit RT dose, is associated with a lower incidence of SNs.
第二原发肿瘤(SNs)是放射治疗(RT)的一种公认的长期不良效应,但关于其在颅脊髓照射(CSI)后髓母细胞瘤(MB)幸存者中的发生率和位置与放射野的关系,数据有限。
通过系统评价和荟萃分析的首选报告项目,对六篇报道了 1114 例接受 CSI 治疗后 MB 幸存者 SNs 发生率和位置的研究进行了系统文献回顾,中位随访时间约为 9 年(7.6-15.4 年)。将研究特异性的 SNs、第二良性肿瘤(SBNs)和第二恶性肿瘤(SMNs)的累积发生率(CI)标准化为 10 年时间框架。使用随机效应模型对来自选定研究和 55 例患者的机构队列的汇总数据进行荟萃分析。
所有 SNs(不包括皮肤癌和白血病)的 10 年 CI 为 6.1%,SBNs 为 3.1%,SMNs 为 3.7%。58%的 SNs 为恶性;高级别胶质瘤是最常见的 SMN(33 例中有 15 例;45%),脑膜瘤是最常见的 SBN(24 例中有 16 例;67%)。40%的 SNs 发生在中枢神经系统(CNS)靶区以外,大多数位于 RT 剂量出口区。74%的 CNS 外肿瘤(23 例中有 17 例)为恶性,最常见的是甲状腺癌(17 例中有 7 例;41%)和骨及软组织肿瘤(17 例中有 6 例;35%)。
MB 幸存者有发生 CNS 内和 CNS 外 SNs 的风险。很大一部分 SNs 发生在 RT 剂量出口区。需要研究质子治疗(无 RT 剂量出口)是否与 SNs 发生率降低有关。